Frangiosa and Associates, LLC was formed to guide organisations on a broad range of strategic decisions, integrating expertise of key strategic partners as required.
Terry has proven success leading the integration of broad perspectives to solve complex business problems, ensuring attainment of top- and bottom-line goals.
Terry began her career in the Pharmaceutical industry at Centocor in 1988. Over 25 years, she has held progressive leadership roles in Strategic Marketing, Marketing Research, and Finance at additional organizations, including Boehringer Mannheim, Gensia-Sicor, Johnson & Johnson and GlaxoSmithKline. She has successfully delivered strategic and tactical programs on product commercialization teams across a variety of therapeutic areas, including Neuroscience (Risperdal, Invega, Invega Sustenna, Concerta), GI (Aciphex), Antifungals (Sporanox, Nizoral), Oncology (etoposide), and CV (Demadex), culminating with a role as a Global Launch Leader for the multi-billion dollar drug Risperdal in Bipolar Disorder, resulting in a multi-billion dollar sales increase for that product.
Additionally, Terry has overseen Early Product Development (neuroscience, oncology, women’s health) and Disease Strategy development (neuroscience, hematology, and kidney disease) that has resulted in product succession through all stages of development, as well as decisions to discontinue non-value added offerings. She also designed and led a Commercial Integrative Solutions Group for Johnson & Johnson, leading development of holistic disease area strategies ‘beyond the pill’ and a process for commercial evaluations of unique business models. Terry received her BA (Accounting) from Ursinus College (Pennsylvania) and her MBA (Pharmaceutical Marketing) from St. Joseph’s University (Pennsylvania)